08/06/2026
Imagine a new medication was launched today.
✅ Supported by Cochrane reviews
✅ Backed by decades of research
✅ Recommended in international guidelines
✅ Proven to improve outcomes in
Most of us would be talking about it nonstop.
But what if I told you that medication already exists?
And many clinicians still don't prescribe it regularly.
The medication is Acamprosate
Why does one of the strongest based treatments in continue to receive less attention than newer and more frequently discussed options?
Is it the dosing?
Is it marketing?
Is it patient selection?
Or is it simply that evidence alone doesn't determine what gets prescribed?
These are some of the questions we'll be exploring today in:
🎙️ Where Does Acamprosate Stand Today? A Clinical Efficacy Perspective
I'm honoured to be joined by an outstanding panel of experts.
A special mention to .prateekrajput Rajput whose practical insights and extensive experience in treatment consistently make academic discussions more relevant to real-world clinical practice.
📌 Quick poll:
Which medication do you reach for most often in relapse prevention?
1️⃣ Acamprosate
2️⃣ Naltrexone
3️⃣ Baclofen
4️⃣ Other
Comment your answer below. 👇
📩 Want the joining link? Comment ACAMPROSATE or send me a DM.
—
Dr. Sidharth Sood
MBBS (MAMC), MD& DNB Psychiatry
DM Addiction Psychiatry (NDDTC, AIIMS New Delhi)
Super Specialist and Consultant Psychiatrist